Affinity DataKi: 2.20nM ΔG°: -49.4kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 3.10nM ΔG°: -48.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 5.30nM ΔG°: -47.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 13nM ΔG°: -45.0kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 20nM ΔG°: -43.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 26nM ΔG°: -43.3kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 27nM ΔG°: -43.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 34nM ΔG°: -42.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 36nM ΔG°: -42.5kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 58nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 63nM ΔG°: -41.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 96nM ΔG°: -40.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 101nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 102nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 103nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 138nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 160nM ΔG°: -38.8kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 166nM ΔG°: -38.7kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 169nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 170nM ΔG°: -38.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 310nM ΔG°: -37.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 320nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 355nM ΔG°: -36.8kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 360nM ΔG°: -36.8kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 470nM ΔG°: -36.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 531nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 980nM ΔG°: -34.3kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 1.16E+3nM ΔG°: -33.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 1.42E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 1.52E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.50E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.50E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 5.49E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
3-Dimensional Pharmaceuticals
Curated by ChEMBL
3-Dimensional Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 6.00E+3nMAssay Description:Inhibition of Human kidney cell urokinaseMore data for this Ligand-Target Pair
Affinity DataKi: 8.90E+3nM ΔG°: -28.8kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: >1.28E+4nM ΔG°: >-27.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: >1.28E+4nM ΔG°: >-27.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: >1.28E+4nM ΔG°: >-27.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: >1.28E+4nM ΔG°: >-27.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: >1.28E+4nM ΔG°: >-27.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) was incubated with compound in reaction buffer. Control reactions were run in each plate. ...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor [538-678,753-922](Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 49nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor [538-678,753-922](Human Sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 57nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
Affinity DataIC50: 57nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 160nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) was incubated with compound in reaction buffer. Control reactions were run in each plate. ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor [538-678,753-922](Human Sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
Ligand Info
TargetMacrophage colony-stimulating factor 1 receptor [538-678,753-922](Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 1.30E+3nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
TargetMacrophage colony-stimulating factor 1 receptor [538-678,753-922](Homo sapiens (Human))
Johnson & Johnson Pharmaceutical
Johnson & Johnson Pharmaceutical
Affinity DataIC50: 1.30E+3nMpH: 7.5 T: 2°CAssay Description:The full-length cFMS cytoplasmic domain (FMS.538-972.6His) or chimera was incubated with compound in reaction buffer. Control reactions were run in e...More data for this Ligand-Target Pair
Ligand Info